Related Experiment Video

Updated: Nov 1, 2025

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.3K

Don't we forget about biological therapy of hypercholesterolemia with PCSK9-inhibitors?

Vladimír Soška, Ondřej Kyselák

    Vnitrni Lekarstvi
    |June 26, 2021
    PubMed

    Insights

    Achieving low LDL-cholesterol is challenging for preventing cardiovascular events. When statins and ezetimibe are insufficient, PCSK9 inhibitors offer significant LDL-CH reduction and risk decrease.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Achieving very low LDL-cholesterol targets for atherosclerotic cardiovascular event prevention is difficult for many patients.
    • Current therapies like statins and ezetimibe may not be sufficient to reach these goals.

    Purpose of the Study:

    • To discuss the role of PCSK9 inhibitors in managing hyperlipidemia when standard therapies fail.
    • To highlight the efficacy and indications for PCSK9 inhibitors in high-risk patients.

    Main Methods:

    • Review of current clinical guidelines and evidence regarding PCSK9 inhibitor use.
    • Analysis of PCSK9 inhibitors' impact on LDL-cholesterol reduction and cardiovascular event risk.

    Main Results:

    • PCSK9 inhibitors reduce LDL-cholesterol by an average of 50-60%.
    • These inhibitors are effective in reducing the risk of atherosclerotic cardiovascular events.
    • Indications include patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia not at LDL-cholesterol goal despite maximal therapy, and in cases of statin intolerance.

    Conclusions:

    • PCSK9 inhibitors are a valuable therapeutic option for patients unable to reach LDL-cholesterol targets with conventional treatments.
    • Their use is crucial for managing high-risk individuals and improving cardiovascular outcomes.

    Keywords:
    LDL-cholesterolPCSK9-inhibitorsatherosclerotic cardiovascular diseasecardiovascular riskdyslipidemiefamilial hypercholesterolemiamixed dyslipidemiastatins

    More Related Videos

    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

    Published on: November 17, 2018

    13.7K
    A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes10:56

    A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

    Published on: September 15, 2018

    8.3K

    Related Concept Videos

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    1.1K
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
    85
    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

    Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
    TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
    298
    Coronary Artery Disease IV: Preventive Measures01:26

    Coronary Artery Disease IV: Preventive Measures

    Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
    431
    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

    Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
    Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
    293
    Cholesterol: Significance and Regulation01:29

    Cholesterol: Significance and Regulation

    Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
    Considering cholesterol and...
    877